NCT00617201 is a Phase 2 clinical trial of atomoxetine in Substance Abuse, sponsored by Sharon Walsh.

Who is sponsoring NCT00617201?

NCT00617201 is sponsored by Sharon Walsh.

What drugs are being tested in NCT00617201?

Interventions in NCT00617201: atomoxetine, placebo.

What condition does NCT00617201 study?

NCT00617201 studies Substance Abuse.

Is NCT00617201 still recruiting?

NCT00617201 is currently completed. Last updated 1 August 2017.

Are results published for NCT00617201?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2017-08-01 · How we verify

NCT00617201

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of Atomoxetine for Cocaine Dependence: A Pilot Trial

Completed Phase 2 Results posted Last updated 1 August 2017

What this trial tests

Phase 2 trial testing atomoxetine in Substance Abuse in 50 participants. Completed in 1 August 2011.

Timeline

1 July 2007

Primary endpoint
1 August 2011

1 August 2011

Quick facts

Lead sponsor	Sharon Walsh
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	50
Start date	1 July 2007
Primary completion	1 August 2011
Estimated completion	1 August 2011
Sites	1 location across United States

Drugs / interventions tested

atomoxetine (ATOMOXETINE) — full drug profile →
placebo

Conditions studied

Substance Abuse — all drugs for Substance Abuse →

Sponsor

Sharon Walsh — full company profile →

Who can join

Adults 18 to 60, any sex, with Substance Abuse. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

% Urine Samples Negative for Cocaine
Time frame: Urines were collected 3 times per week (e.g., Monday, Wednesday and Friday) for 12 weeks
Total % urine samples negative for benzoylecgonine over the 12-week trial

Sponsor's own description

This placebo-controlled, double-blind, randomized pilot clinical trial will evaluate atomoxetine (Strattera®) for the treatment of cocaine dependence. Cocaine-dependent individuals, who are healthy and are seeking treatment for their substance abuse, will be randomized to receive either atomoxetine (n=25) or a matched-placebo (n=25) during a trial lasting 12 weeks; there will be a double-blind, ascending dose lead-in order to achieve maintenance on the assigned active dose safely. Contingency management procedures will be used to reinforce attendance and compliance with study procedures. Primary outcome measures will include urinalysis data assessing cocaine use.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Atomoxetine does not alter cocaine use in cocaine dependent individuals: double blind randomized trial.
Walsh SL, Middleton LS, Wong CJ, Nuzzo PA, et al · · 2013 · cited 26× · PMID 23200303 · DOI 10.1016/j.drugalcdep.2012.10.024

Verify or expand the search:

Other recruiting trials for Substance Abuse

Currently open trials in the same condition.

NCT06627764 — SER Familia: A Family-Based Intervention Addressing Syndemic Conditions Among Latino Immigrant Families · NA · recruiting
NCT06899308 — Health Surveillance at Constructor University Bremen (CUB) and Among HAW-Hamburg Employees · recruiting
NCT06880705 — The Trans-Led Care Study · NA · recruiting
NCT06852170 — Data2Action Oregon Project: Supporting Data-driven Decision-Making for Substance Use Services, Policy, and Overdose Prev · NA · recruiting
NCT05776316 — Harm Reduction Services · NA · recruiting

Other Sharon Walsh trials

Trials by the same sponsor.

NCT04300751 — The Behavioral Effects of Opioids and Alcohol · Phase 1 · completed
NCT04315181 — Prescription Medication Interactions · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00617201 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sharon Walsh
Last refreshed: 1 August 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00617201.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing